Virpax Pharmaceuticals is a leading brand that is revolutionizing pain management for both prescribers and patients. They are committed to developing non-addictive product candidates that effectively manage severe pain while minimizing risks. Their flagship product candidate, Probudur, utilizes next-generation liposomal encapsulation to deliver a biphasic release of local anesthetic at the wound/incision site, providing fast onset and long-duration pain control for up to 96 hours after surgery.

In addition to pain management, Virpax is also focused on directly targeting the brain to manage Central Nervous System (CNS) disorders. Their patented Molecular Envelope Technology (MET) platform is being harnessed to develop treatments for CNS disorders such as Post Traumatic Stress Disorder (PES200) and Rare Pediatric Epilepsy (NobrXiol). This innovative drug delivery process directly targets the brain to effectively manage symptoms.

Virpax is dedicated to transforming drug-delivery technologies and is actively seeking FDA approval for their robust pipeline. If approved, their product candidates will fundamentally change how prescribers manage severe pain, epilepsy, and other CNS disorders in the future. With a strong focus on non-addictive treatments and rare diseases, Virpax is poised to make a significant impact on the medical field